ArticleJournal of neuro-oncology2025
Rapid early progression of glioblastoma: evaluation of a novel prognostic radiologic biomarker.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical outcomes of early salvage surgery for residual or enlarging contrast-enhancing lesions after radiotherapy in patients with glioblastoma.Frontiers in oncology · 2026Article
- Longitudinal Cerebral Structural, Microstructural, and Functional Alterations After Brain Tumor Surgery for Early Detection of Recurrent Tumors.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRapid Early Progression (REP) in glioblastoma occurs when there is tumor growth between the immediate postoperative MRI and the radiotherapy planning MRI. We reviewed a large multicenter series to determine the frequency, predictors, and impact of REP.
methodsPatients treated with radiotherapy for newly-diagnosed glioblastoma between 2014 and 2023 were reviewed. Preoperative/postoperative MRIs were individually reviewed to determine radiographic extent of resection (EOR) as either gross-total (GTR), near-total (NTR), subtotal (STR), or biopsy. Radiotherapy-planning MRIs were evaluated for REP and classified as clear, mild, or none; and REP location as local, distant, or both. Progression-free survival (PFS), overall survival (OS), and predictors for REP were analyzed and compared.
resultsFour hundred and one (401) patients met inclusion criteria. REP was seen in 62.1% of patients. Compared to patients with GTR, increased REP was seen in patients with NTR (OR = 7.94, p < 0.001), STR (OR = 15.12, p < 0.001), and biopsy (OR = 6.52, p < 0.001). Time from resection to radiotherapy-planning MRI was not associated with REP (p = 0.611). REP predicted inferior PFS (p = 0.011) with further decrease seen in clear REP (HR = 1.713, 95% CI: 1.202-2.441) as compared to mild REP (HR = 1.511, 95% CI: 1.046-2.183).
conclusionThese data support REP as a common and practical biomarker suggestive of more aggressive tumor phenotype. REP was strongly associated with EOR (although not with delays to radiotherapy) and associated with decreased PFS. Novel strategies are needed to integrate REP into clinical trial stratification, predict for REP a priori, reduce its frequency, and/or tailor adjuvant therapy.
Indexed as
Identifiers
41085838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.